70 results about "Verapamil" patented technology

The present invention relates to compositions for oral administration. The invention preferably comprises at least one abuse-resistant drug delivery composition for delivering a drug having potential for dose dumping in alcohol, related methods of preparing these dosage forms, and methods of treating a patient in need thereof comprising administering the inventive compositions to the patient. Most preferably, the dosage form includes verapamil. These formulations have reduced potential for abuse. In another formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.

The present invention relates to compositions for oral administration. The invention preferably comprises at least one abuse-resistant drug delivery composition for delivering a drug having potential for dose dumping in alcohol, related methods of preparing these dosage forms, and methods of treating a patient in need thereof comprising administering the inventive compositions to the patient. Most preferably, the dosage form includes verapamil. These formulations have reduced potential for abuse. In another formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.

The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to treatment or prevention of ischemic events in patients with cardiovascular disease. The present invention is particularly useful for patients having or being at increased risk of development of an ischemic event such as an acute myocardial infarction and / or no-reflow phenomena and / or ischemia-reperfusion injury by administration of agent(s) modulating and / or preserving endothelial integrity. The compounds may be administered in combination with standard treatment of acute cardiovascular ischemic events such as Platelet inhibitors such as aspirin (ASA), Thienopyridins, GPIIb / IIIa inhibitors), Parenteral anticoagulants such as unfractioned heparin (UFH), bivalirudin, enoxaparin, and fondaparinux, Verapamil, Adenosine, Sodium nitroprusside, Nitroglycerin, Epinephrine, Beta-blockers and surgical methods such as percutaneous coronary intervention (PCI), PCI with thrombus aspiration, PCI with stents.

A pharmaceutical dosage form comprises, in one portion thereof, a substantially single (+)-enantiomer of a chiral drug other than verapamil and, in another, separate portion thereof, a substantially single (-)-enantiomer of the drug wherein, in use, the different enantiomers are released at different rates from the dosage form. The dosage form is useful for administration of chiral drugs where both enantiomers have a valid pharmacological input, and where a clinical benefit may be realised by controlling the release rates of those enantiomers. Examples of such drugs include, in particular, tramadol and warfarin.

A pharmaceutical dosage form comprises, in one portion thereof, a substantially single (+)-enantiomer of a chiral drug other than verapamil and, in another, separate portion thereof, a substantially single (-)-enantiomer of the drug wherein, in use, the different enantiomers are released at different rates from the dosage form. The dosage form is useful for administration of chiral drugs where both enantiomers have a valid pharmacological input, and where a clinical benefit may be realised by controlling the release rates of those enantiomers. Examples of such drugs include, in particular, tramadol and warfarin.

A pharmaceutical composition comprising a solid unit dosage form comprising: one or more of pharmaceutically active ingredients selected from valacyclovir, olanzapine, voriconazole, topotecan, artesunate, amodiaquine, guggulosterone, ramipril, telmisartan, tibolone, atorvastatin, simvastatin, amlodipine, ezetimibe, fenofibrate, tacrolimus, valgancyclovir, valsartan, clopidrogel, estradiol, trenbolone, efavirenz, metformin, pseudoephedrine, verapamil, felodipine, valproic acid / sodium valproate, mesalamine, hydrochlorothiazide, levosulpiride, nelfinavir, cefixime and cefpodoxime proxetil in combination with a water insoluble polymer and / or a water soluble polymer. Methods for making the pharmaceutical composition are also disclosed.

A polymer-surfactant nanoparticle formulation, using the anionic surfactant aerosol OT (AOT) and polysaccharide polymer alginate, is used for sustained release of water-soluble drugs. The AOT-alginate nanoparticles are suitable for encapsulating doxorubicin, verapamil and clonidine, as well as therapeutic agents effective against dermal conditions such as psoriasis. The nanoparticles are also suitable for encapsulating photo-activated compounds such as methylene blue for use in photo-dynamic therapy of cancer and other diseases, and for treating tumor cells that exhibit resistance to at least one chemotherapeutic drug.

The invention discloses verapamil liposome and a preparation method of the verapamil liposome, belonging to the technical field of medicine. The verapamil liposome is composed of verapamil, phospholipid, cholesterol, chitosan, cationic lipid and antioxidant, etc., all of which are in certain weight percentage. The verapamil liposome is prepared by adopting ammonium sulphate gradients method, film hydration method, ethanol injection method and reverse phase evaporation method. The invention adopts chitosan or derivatives of the chitosan to modify the surface of the liposome, and applies the chitosan to ophthalmic preparation, which can further increase corneal retention of the liposome and can remarkably improve the corneal penetration amount of the drug, with obvious advantages compared with ordinary liposome. With high entrapment efficiency, good stability, good biocompatibility, biological adhesiveness and biodegradability, the prepared liposome can realize sustained release and long-acting administration, particularly suitable for administration on ocular region, and can better play the ocular effects of anti-glaucoma and anti-cataract of verapamil.

Methods of cooling blood platelet suspensions which can be stored and preserved for extended periods of time. The normal morphology of platelets and their ability to function are substantially maintained. The steps include preparing a platelet suspension having blood platelets, a carbohydrate and at least one biocompatible polymer to assist in stabilizing platelet membranes. The platelet suspension may be cooled to a temperature of less than approximately 10 degrees C. at a rate of cooling greater than 1 degree C. / min. The platelet suspension may be kept at a storage temperature ranging from approximately -1 to 6 degrees C. Additionally, methods are provided for maintaining the biological activity of blood platelets. Platelet suspensions may be initially prepared which include platelets, sucrose, verapamil, magnesium chloride and a biocompatible polymer. Cooling of the platelet suspension may be followed at a cooling rate ranging from approximately 1 to 12 degrees C. / min or faster to a temperature below 10 degrees C. The cooled platelet suspension may be thus stored at a storage temperatures as high as 6 degrees C.

A pharmaceutical dosage form comprises, in a portion thereof, substantially single enantiomer (R)-verapamil and, in another, separate, portion thereof, substantially single enantiomer (S)-verapamil, wherein, in use, the different enantiomers are released at different rates from the dosage form.

The invention discloses an umbilical cord preservation fluid and an umbilical cord preservation method. The umbilical cord preservation fluid is prepared from 15-20 mmol of hyperbranched polyglycerol,99-101 mmol of lacturonic acid, 24-26 mmol of monopotassium phosphate, 4-6 mmol of magnesium sulfate, 4-6 mmol of adenosine, 2-4 mmol of glutathione reduction type, 6-10 mg of dexamethasone, 0.5-1.5mmol of allopurinol, 50-70 mmol of sucrose, 40-60 g of dextran, 18-22 mg of verapamil, 4-6 ml of sodium hydroxide and 19-21 ml of potassium hydroxide. When an umbilical cord is preserved , the cleanedumbilical cord is cut into small sections with the length of 3-5 cm, then immersed into a preservation liquid and preserved in an environment with the temperature of 3-5 DEG C. By adopting the preservation liquid, the problem that the umbilical cord cannot be preserved for a long time after being isolated can be effectively solved.

The invention relates to a method for detection of P-glycoprotein (P-gp) mediated rhodamine 123 (Rh123) transport in a 3D type organ and an application thereof in screening of P-gp inhibitors. The method comprises the steps: firstly, sorting small intestinal crypts of C57BL / 6 mice, inoculating a petri dish containing a matrix gel, culturing in an Advanced DMEM / F12 culture medium, and forming the 3D type organ; and then carrying out qualitative and quantitative detection of P-gp mediated Rh123 transport and influence of the P-gp inhibitor verapamil on Rh123 transport by using the 3D type organ model. The method particularly comprises the steps of respectively co-incubating the 3D type organ with (1) the P-gp substrate Rh123 and with (2) the Rh123 and the verapamil, releasing the Rh123 in the 3D type organ by using an ultrasonic crushing method, and finally detecting the concentration of the Rh123 on a multifunctional microplate reader. The method has the advantages of being simple, rapid, and high in sensitivity, can be combined with the 3D type organ model for carrying out research of the P-gp mediated drug transport, and also can perform research of in-vitro screening of the P-gp inhibitors.

The present invention relates to a kind of pharmaceutical composition, it comprises telmisartan salt and calcium ion antagonist or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier; Described telmisartan salt is selected from telmisartan Sodium salt, potassium salt, calcium salt, magnesium salt or amine salt of sartan, described calcium ion antagonist is selected from amlodipine, lacidipine, cilnidipine, lercanidipine, nisoldipine, nica Dipine, azedipine, barnidipine, manidipine, benidipine, verapamil, diltiazem, or a pharmaceutically acceptable salt thereof. The composition is used for preventing, delaying progress or treating patients with hypertension, angina pectoris, atherosclerosis, stroke, cardiac insufficiency, dyslipidemia, diabetes, renal function damage or hypertension accompanied by Alzheimer's disease, reducing Reduce the morbidity and / or mortality of cardiovascular and cerebrovascular diseases, reduce adverse drug reactions, and improve patients' compliance with medication.

The present disclosure in various embodiments teaches methods of treating patients in need of treatment with a Factor Xa inhibitor, and who are also concomitantly administered verapamil.

The invention, which belongs to the technical field of medicines, relates to a preparation method for a bio-affinity chromatography column rich in P-glycoprotein and application thereof. A plasma membrane rich in P-glycoprotein is extracted from a Caco-2 cell and, together with an amino-bonded silica gel, forms a P-glycoprotein bio-affinity chromatography column; the constructed P-glycoprotein bio-affinity chromatography column is applied to the chromatographic analysis to verify the specific binding with the drug using the P-glycoprotein as a target; and the P-glycoprotein bio-affinity chromatography column has the specific affinity adsorption function to the P-glycoprotein-positive drug verapamil but has no absorption function to the drug with the non-P-glycoprotein target. Therefore, anovel method is provided for screening the P-glycoprotein target drug. After performance evaluation, the prepared P-glycoprotein bio-affinity chromatography column is demonstrated to have advantages of high specificity and stability and long service life and thus has the broad application prospects.

The invention relates to a compound and a salt thereof in a general formula (I). The compound has strong reversal tumor multidrug resistance (MDR), and has small cytotoxicity, and the activity is much higher than that of verapamil. The invention also relates to a preparation method of the compound and a medicinal preparation containing the compound. The general formula (I) is as shown in the specification.

The invention relates to a compound as shown in the general formula (I) and salt thereof. The compound has the effect of high reversal of tumor multidrug resistance (MDR). The activity is far higher than that of verapamil, and the cytotoxicity is small. The invention further relates to a preparation method of the compound and a pharmaceutic preparation containing the compound. (Please see the specification for the formula)

The present disclosure in various embodiments teaches methods of treating patients in need of treatment with a Factor Xa inhibitor, and who are also concomitantly administered aspirin and verapamil.

The invention relates to an application of p-hydroxyphenylacetic acid in prevention and / or treatment of cardiovascular diseases. The invention finds for the first time that p-hydroxyphenylacetic acidhas a good treatment effect on vascular and cardiac injuries. For zebra fish interbody vascular (ISV) injury and subintestinal vein (SIV) growth conditions induced by a vascular endothelial cell growth factor receptor inhibitor (PTK787), p-hydroxyphenylacetic acid has a remarkable effect of promoting angiogenesis, and the generation number and the length of blood vessels can be obviously increased. The traditional Chinese medicine composition has a remarkable heart protection effect on heart failure of zebra fish induced by verapamil, arrhythmia induced by terfenadine and p-hydroxyphenylaceticacid, and can obviously reduce cardiac dilatation, relieve venous congestion and promote the heart rate to tend to be normal.

The present invention relates to application of bellidifolin and an extract thereof in preparations of drugs for prevention and treatment of cardiacarrhythmia. The present invention further discloses a drug composition, wherein the drug composition comprises bellidifolin adopted as an active ingredient or a pharmaceutically-acceptable carrier thereof, and an excipient or a diluent. Results of pharmacological experiments show that: the bellidifolin and the extract thereof have anti-cardiacarrhythmia effects, provide strong cardiacarrhythmia prevention activities compared with the control group, and provide the similar pharmacological properties compared with the positive control group of verapamil. In addition, the experimental study results of the present invention provide strong experimental supports for reasonable application of gentianella acuta traditional Chinese drug.

The invention relates to compounds shown as a general formula (I) and salt thereof. The compounds have strong reverse tumor multidrug resistance (MDR) effect, activity of part of the compounds is far higher than verapamil, and the compounds have low cytotoxicity. The invention further relates to a medicinal preparation containing the compounds. A series of the compounds shown as the general formula (I) and the pharmaceutically acceptable salt thereof are synthesized.

The invention discloses a pharmaceutical composition for treating acute lung injury and belongs to the technical field of biopharmaceutical industry. The pharmaceutical composition comprises the following main components in parts by weight: 20-25 parts of puerarin, 0.2-0.4 part of verapamil, 1-2 parts of ulinastatin, 0.6-0.8 part of an NE inhibitor, 0.3-0.6 part of a salviae miltiorrhizae water extract and 0.4-0.8 part of glutamine. The invention provides the pharmaceutical composition for treating acute lung injury. By means of matched use of puerarin and verapamil, the pharmaceutical composition can effectively treat acute lung injury and inhibit rise of content of blood serum TNF-alpha, alleviate PMN infiltration, eliminate free radicals and alleviate the extent of lung tissue edema, and has an effective protecting action on acute lung injury; and moreover, the oxygenation index of arterial partial pressure of oxygen is obviously increased, and the respiratory function of a patient is improved. The pharmaceutical composition disclosed by the invention not only can treat acute lung injury effectively, but also plays a maintaining role on lungs, and is convenient to use and low in cost.

Disclosed is a medicine for treating tumor which is a composition prepared from arsenic trioxide and verapamil by the weight ratio of 5 : 1-2 :1 wherein the verapamil has inhibitory action to both activated and deactivated L-type calcium passages, the effect for the treatment can be improved.

The present disclosure in various embodiments teaches methods of treating patients in need of treatment with a Factor Xa inhibitor, and who are also concomitantly administered verapamil.

The invention provides a liver perfusate, which is prepared by 5,500 to 6,500 mg / L of sodium chloride, 250 to 350 mg / L of potassium chloride, 150 to 250 mg / L of calcium chloride, 3,000 to 3,200 mg / L of sodium lactate, 4 to 6 mmol / L of 1, 6-diphosphofructose, 5 to 15 mg / L of dexamethasone, 2.5 to 3.5 mmol / L of reduced glutathione, and 4 to 6mg / L of verapamil. The product has a simple formula, convenient configuration, low cost and proper potassium concentration, can be safely used for the preservation of isolated organs, more importantly can be applied to the perfusion protection of in vivo organs, and can effectively prevent the injury of hepatic ischemia reperfusion. The invention also provides two preparation methods for the liver perfusate.

The invention relates to a compound anti-arrhythmic drug which is composed of a calcium antagonist verapamil or diltiazem and digitalis drug. The positive inotropic effect of the digitalis drug can resist the negative inotropic effect of the verapamil or the diltiazem, while the effect of delaying the atrioventricular conduction thereof can strengthen the treatment effect of delaying the atrioventricular conduction of the verapamil or the diltiazem. In the compound drug, the used dose of the verapamil or the diltiazem is reduced, thus increasing safety and expanding scope of application.

Disclosed herein are methods for treating conditions and / or disorders related to hyperglycemia. Such conditions and / or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof in the treatment of conditions and / or disorders related to hyperglycemia.

The invention discloses a paediatric internal medicine center acute suppurative tonsillitis treating drug. The paediatric internal medicine center acute suppurative tonsillitis treating drug is mainlycomposed of raw materials including, by weight part, 8-14 parts of cefamandole, 14-17 parts of vicenin, 5-8 parts of physcion 8-O-beta-D-monoglucoside, 3-5 parts of 5-aminosalicylic acid, 16-27 partsof herba houttuyniae extract, 3-5 parts of coptis chinensis extract, 2-4 parts of hypoxanthine nucleotide, 6-8 parts of menthol, 5-10 parts of luteolin, 11-16 parts of baicalin, 1-8 parts of curzerene, 2-4 parts of borneol, 0.5-1.2 parts of verapamil and 1-5 parts of vitamin B. The paediatric internal medicine center acute suppurative tonsillitis treating drug achieves the aim of comprehensive rehabilitation, is rapid in effects on illness of patients, good and stable in therapeutic effects and convenient to carry and take, and can timely cure the diseases of the patients, avoid disease deterioration, minimize damage of tonsillitis to body of the patients, resist inflammation and relieve swelling and pain, reduce exudation of interstitial fluid and cell sap and promote tissue restoration.

The invention relates to compounds as shown in a formula (I) and salt thereof. The compounds have relatively high action of reserving multidrug resistance (MDR) of tumors and the activity of part of the compounds is higher than that of verapamil, and the compounds have smaller cytotoxicity. The invention also relates to a drug preparation containing the compounds. A series of compounds as shown inthe formula (I) and pharmaceutically acceptable salt are synthesized. The formula is as shown in the specification.

The invention relates to a function of phencynonate hydrochloride in preparing medicine for treating or relieving myocardial damage induced by myocardial ischemia reperfusion. In a myocardial ischemia reperfusion damage animal model of a rat or a rabbit, the phencynonate hydrochloride can obviously restrain the myocardial damage caused by the myocardial ischemia reperfusion, and the function is basically similar to positive therapeutic verapamil and is free of side effects of low blood pressure, slowing of heart rate of the verapamil.